Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects

AIMS: Soticlestat is a first‐in‐class selective inhibitor of cholesterol 24‐hydroxylase, the enzyme that converts brain cholesterol to 24S‐hydroxycholesterol (24HC), a positive allosteric modulator of N‐methyl‐D‐aspartate receptors. Soticlestat is under development as treatment for rare developmenta...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shining, Chen, Grace, Merlo Pich, Emilio, Affinito, John, Cwik, Michael, Faessel, Hélène
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597018/
https://www.ncbi.nlm.nih.gov/pubmed/33837574
http://dx.doi.org/10.1111/bcp.14854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597018/
https://www.ncbi.nlm.nih.gov/pubmed/33837574
http://dx.doi.org/10.1111/bcp.14854

Ejemplares similares